Abstract: Methods and reagents are provided for determining the activation state of a signal transduction pathway signaling protein. There exists a need in the art for methods that can monitor the efficacy of a signal transduction inhibitor in a patient. Other needs exist for detecting and monitoring certain disease or disorders that are associated with aberrant activation of a signal transduction pathway signaling protein. The present assay provides a highly sensitive assay that is also useful in patient populations in which obtaining a large cellular sample is difficult, for example, neonates.

Abstract: The present invention is directed to novel synthetic methods for preparing a spiro cyclopropyl indolinone compound represented by Structural Formula (A): or its pharmaceutically acceptable salt thereof. Also included are synthetic intermediates described herein.

Abstract: A connector apparatus has a first portion and a second portion. The first portion mounts to an upright that has knobby hand grip protrusions. The second portion provides a connection for a laterally extending cross-member. The first portion interacts with the knobby hand grip protrusions to have a combination of a first degree of freedom permitting motion in one direction, while inhibiting motion in a second degree of freedom. The second portion has a releasable connection to the cross-member, and when engaged, has a degree of freedom of motion about an axis of the second portion cross-wise to the axis of the upright. The second portion has a releasable, retained, pin connector with a quarter-turn lock to prevent accidental disengagement. The connection of the second portion is offset such that when two connectors are seated back-to-back their cross-tie connections stand in substantially the same horizontal plane relative to the ground.

Abstract: A cantilevered support system is provided. The cantilevered support system comprises a vertical support pole and longitudinally extending upper and lower support arm assemblies that are securable to a wall.

Abstract: A method of expanding double negative T cells in culture is described. The method comprises (a) providing a starting sample comprising DN T cells or precursors thereof; (b) substantially depleting CD8+ and CD4+ T cells from the starting sample; (c) culturing the sample from step (b) with an immobilized T cell mitogen in a culture medium comprising an agent that can stimulate DN T cell growth; (d) washing the cells obtained in step (c) and resuspending in a culture medium comprising the agent without the T cell mitogen; and (e) washing the cells obtained in step (d) and resuspending in a culture medium comprising the agent and a soluble T cell mitogen. The DN T cells obtained by the method are useful in a variety of applications including the treatment of cancer, infectious diseases, graft versus host disease and autoimmune disease.

Abstract: There is herein described a nanovesicle comprising a bilayer of porphyrin-phospholipid conjugates. Each porphyrin-phospholipid conjugate comprises one porphyrin, porphyrin derivative or porphyrin analog covalently attached to a lipid side chain at one of the sn-1 or the sn-2 positions of one phospholipid. Further, the nanovesicle has a defined regioisomeric ratio of sn-1:sn-2 porphyrin-phospholipid conjugates.

Abstract: Herein are provided nano-particles comprising a nanocore of Raman-scattering material stabilized by a bilayer comprising a porphyrin-phospholipid conjugate, methods of making the same and their use in Surface Enhanced Raman Scattering.

Abstract: Methods and compositions for producing NKX6-1+ pancreatic progenitor cells and/or insulin producing cells from an endodermal cell population, the method comprising contacting the endodermal cell population with an EGF component, a Nicotinamide component and/or a Noggin component, optionally a combination of at least one EGF component and at least one nicotinamide component to induce the differentiation of at least one endodermal cell into a NKX6-1+ pancreatic progenitor cell, the combination optionally further comprising at least one Noggin component.

Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

Abstract: A fiber optic dosimeter probe for sensing radiation dose including an optical fiber having a free end and a sensitive end, a window having a sensitive side and a rear side; a radiation sensitive layer between the sensitive end of the optical fiber and a sensitive side of the window, the radiation sensitive layer being made of a material having an optical property that changes with absorbed radiation dose, an amount of the material corresponding to a predetermined sensitivity to radiation; wherein the window and the optical fiber have a near water equivalent interaction with radiation and are MR compatible.

Abstract: The present teachings provide a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

Abstract: Provided herein are methods, uses and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist, and identifying a patient that is likely to be responsive to PLK4 antagonist therapy, if PTEN gene mutation is present.

Abstract: The present invention is directed to novel synthetic methods for preparing a spiro cyclopropyl indolinone compound represented by Structural Formula (A): (A) or its pharmaceutically acceptable salt thereof. Also included are synthetic intermediates described herein.

Abstract: The present teaching provide indazole compounds represented by Structural Formulae (I) or (I?) or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as TTK protein kinase, polo-like kinase 4 (PLK4) and Aurora kinases having anticancer activity against breast cancer cells, colon cancer cells, and ovarian cancer cells.

Abstract: Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.

Abstract: There is described herein methods and peptides for detecting autoantibodies to NOG and/or SOST in a patient sample in order to diagnose of prognosticate Ankylosing Spondylitis in the patient.

Abstract: An imaging phantom for contrast imaging calibration. The phantom includes a body defining at least one cavity having a directional configuration corresponding to at least one pre-determined direction of motion of the phantom. The phantom also includes at least one imaging capsule configured to match and be contained in the at least one cavity. The imaging capsule comprises a material having an imaging contrast different from that of the body.

Abstract: Disclosed herein is a functional electrical stimulation (FES) device and system. In one embodiment, sequential bipolar pulse stimulation may be provided to an area of a living body via one or more electrode leads applied to the area via a FES device comprising a current pulse generating circuit comprising output nodes for operative coupling to the one or more electrode leads, and configured for operative coupling to a voltage supply. The current pulse generating circuit generally comprises positive and negative stimulation paths drawing from the voltage supply to respectively apply positive and negative currents through the area via the one or more electrode leads. In one example, the stimulation paths comprise respective capacitive elements, a capacitance ratio of which dictating, at least in part, an amplitude ratio of the positive and negative currents, wherein periodic alternative activation of the stimulation paths provides the sequential bipolar pulse stimulation.

Abstract: This document involves methods and materials related to inhibiting cyclin D polypeptide activity. For example, this document provides methods and materials that can be used to (1) identify mammals or cells in need of cyclin D polypeptide inhibition and (2) administer an agent capable of inhibiting cyclin D polypeptide activity.

Abstract: The invention relates to modulating the SIRP?—CD47 interaction in order to treat hematological cancer and compounds therefor. In particular, there is also provided SIRP? antibodies and antibody fragments, preferably used for treating hematological cancer.